2,4-二氯苯氧基乙腈 | 3956-63-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,4-二氯苯氧基乙腈
• 中文别名: 2-(2,4-二氯苯氧基)乙腈
• 英文名称: 2-(2,4-dichlorophenoxy)acetonitrile
• 英文别名: (2,4-dichloro-phenoxy)-acetonitrile；(2,4-Dichlor-phenoxy)-acetonitril；2,4-dichlorophenoxyacetonitrile；2-(2,4-Dichlorphenoxy)-acetonitril
• CAS: 3956-63-6
• 化学式: C₈H₅Cl₂NO
• mdl: MFCD00019826
• 分子量: 202.04
• InChiKey: QSDMPLNZSJLFRM-UHFFFAOYSA-N

物化性质

• 熔点：
  46-48°C
• 沸点：
  121-125 °C(Press: 0.5 Torr)
• 密度：
  1.372±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  在常温常压下，该物质稳定。

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xn
• 安全说明：
  S22,S36/37
• 危险类别码：
  R20/21/22
• 海关编码：
  2926909090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险品运输编号：
  3276
• 储存条件：
  常温、避光、通风干燥处，密封保存。

SDS

Name:	2-(2 4-Dichlorophenoxy)acetonitrile 97% Material Safety Data Sheet
Synonym:
CAS:	3956-63-6

Section 1 - Chemical Product MSDS Name:2-(2 4-Dichlorophenoxy)acetonitrile 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
3956-63-6	2-(2,4-Dichlorophenoxy)acetonitrile	97%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 3956-63-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white crystalline solid
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 46 - 48 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H5Cl2NO
Molecular Weight: 202

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents, acids, bases.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, hydrogen cyanide, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 3956-63-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-(2,4-Dichlorophenoxy)acetonitrile - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: NITRILES, SOLID, TOXIC, N.O.S.*
Hazard Class: 6.1
UN Number: 3276
Packing Group: III
IMO
Shipping Name: NITRILES, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3276
Packing Group: III
RID/ADR
Shipping Name: NITRILES, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3276
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 3956-63-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 3956-63-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 3956-63-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,4-二氯苯氧基乙腈 在 sodium hydroxide 作用下， 生成 2,4-二氯苯氧乙酸
  参考文献：
  名称：

  Barber et al., Journal of Applied Chemistry, 1953, vol. 3, p. 266,273

  摘要：

  DOI：
• 作为产物：
  描述：

  (2,4-dichlorophenoxy)acetaldehyde 在 sodium hydroxide 、 盐酸羟胺 、 乙酸酐 作用下， 以 乙醇 、 水 为溶剂， 生成 2,4-二氯苯氧基乙腈
  参考文献：
  名称：

  Khadse, B. G.; Lokhande, S. R.; Bhamaria, R. P., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1987, vol. 26, # 1-12, p. 856 - 860

  摘要：

  DOI：

文献信息

• Development of structure — Activity trends in the series of 3-phenoxychromone derivatives
  作者：S. A. Vasil'ev、V. L. Boyarchuk、M. S. Luk'yanchikov、V. P. Khilya

  DOI：10.1007/bf00767267

  日期：1991.11

  e (IIa-o), containing both electron-donor and electron-acceptor substituents in the phenoxyl part of the molecule. These compounds were obtained by the action of phosphorus chloride on the complex of the compound (Ia-o) with boron trifluoride etherate in dimethylformamide. The acylation of the compound (II) with acetic anhydride in the presence of pyridine gave the corresponding acetates (IIl).

  为了开发具有兴奋和降血脂活性的物质，我们完成了 3-苯氧基-7-氢色酮 (IIa-o) 的合成，在分子的苯氧基部分包含电子供体和电子受体取代基. 这些化合物通过氯化磷对化合物(Ia-o)与三氟化硼醚合物在二甲基甲酰胺中的络合物的作用而获得。在吡啶存在下用乙酸酐酰化化合物(II)得到相应的乙酸酯(IIl)。
• ＳＴＡＴ３ 저해활성을 갖는 화합물 및 이의 용도
  申请人：Seoul National University R&DB Foundation 서울대학교산학협력단(120070509242) Corp. No ▼ 114371-0009224BRN ▼119-82-03684

  公开号：KR101674463B1

  公开（公告）日：2016-11-10

  본 발명은 STAT3 저해활성을 갖는 화합물, 또는 이의 약제학적으로 허용가능한 염, 용매화물 또는 수화물, 그리고 이들의 약제학적 용도에 관한 것이다. 본 발명의 화합물은 다양한 질환과 관련된 STAT3의 비정상적인 활성을 효율적으로 저해시키므로 암, 자가면역 질환, 염증성 질환 등과 관련된 다양한 STAT3 관련 질환에 대한 예방 및 치료 목적으로 유용하게 이용될 수 있다.

  这项发明涉及具有STAT3抑制活性的化合物，或其药学上可接受的盐，溶剂合物或水合物，以及它们在药学上的用途。该发明的化合物可以有效地抑制与多种疾病相关的STAT3异常活性，因此可以用于预防和治疗与癌症，自身免疫性疾病，炎症性疾病等相关的多种STAT3相关疾病。
• COMPOUND HAVING STAT3 INHIBITORY ACTIVITY AND USE THEREOF
  申请人：CYTUS H&B CO., LTD.

  公开号：US20200354327A1

  公开（公告）日：2020-11-12

  The present invention relates to a compound exhibiting STAT3 inhibitory activity, or a pharmaceutically acceptable salt, solvate or hydrate of the same, and pharmaceutical uses of these. The compounds of the present invention efficiently inhibit the abnormal activity of STAT3 associated with various diseases and thus can be usefully utilized for the prevention and treatment of various STAT3-related diseases associated with cancer, autoimmune diseases, inflammatory diseases and the like.

  本发明涉及一种具有STAT3抑制活性的化合物，或其药学上可接受的盐、溶剂或水合物，以及这些化合物的药物用途。本发明的化合物有效地抑制了与各种疾病相关的STAT3异常活性，因此可用于预防和治疗与癌症、自身免疫性疾病、炎症性疾病等相关的各种STAT3相关疾病。
• 피부 미백용 조성물 및 이의 용도
  申请人：Seoul National University R&DB Foundation 서울대학교산학협력단(120070509242) Corp. No ▼ 114371-0009224BRN ▼119-82-03684

  公开号：KR102188791B1

  公开（公告）日：2020-12-09

  본 발명은 피부 미백용 조성물 및 이의 용도에 관한 것으로, 세포 독성을 일으키지 않으며, 멜라닌의 생성을 유도하는 효소 및 전사 인자의 발현 및 활성을 억제하여 피부 미백 효과를 나타낼 수 있다.

  这项发明涉及皮肤美白用配方及其用途，通过抑制酶和转录因子的表达和活性，不会引起细胞毒性，诱导黑色素的产生，从而表现出皮肤美白效果。
• Development of Oxadiazole-Based ODZ10117 as a Small-Molecule Inhibitor of STAT3 for Targeted Cancer Therapy
  作者：Kim、Lee、Song、Park、Gadhe、Choi、Lee、Pae、Kim、Ye

  DOI：10.3390/jcm8111847

  日期：——

  Persistently activated STAT3 is a promising target for a new class of anticancer drug development and cancer therapy, as it is associated with tumor initiation, progression, malignancy, drug resistance, cancer stem cell properties, and recurrence. Here, we discovered 3-(2,4-dichloro-phenoxymethyl)-5-trichloromethyl-[1,2,4]oxadiazole (ODZ10117) as a small-molecule inhibitor of STAT3 to be used in STAT3-targeted cancer therapy. ODZ10117 targeted the SH2 domain of STAT3 regardless of other STAT family proteins and upstream regulators of STAT3, leading to inhibition of the tyrosine phosphorylation, dimerization, nuclear translocation, and transcriptional activity of STAT3. The inhibitory effect of ODZ10117 on STAT3 was stronger than the known STAT3 inhibitors such as S3I-201, STA-21, and nifuroxazide. ODZ10117 suppressed the migration and invasion, induced apoptosis, reduced tumor growth and lung metastasis, and extended the survival rate in both in vitro and in vivo models of breast cancer. Overall, we demonstrated that ODZ10117 is a novel STAT3 inhibitor and may be a promising agent for the development of anticancer drugs.

  持续激活的STAT3是一种新型抗癌药物开发和癌症治疗的有前途的靶点，因为它与肿瘤的起始、进展、恶性程度、药物抵抗、癌症干细胞特性和复发有关。在这里，我们发现3-(2,4-二氯苯氧甲基)-5-三氯甲基-[1,2,4]噁二唑（ODZ10117）是一种小分子抑制剂，可用于STAT3靶向癌症治疗。ODZ10117靶向STAT3的SH2结构域，无论其他STAT家族蛋白和STAT3的上游调节因子如何，都会导致抑制STAT3的酪氨酸磷酸化、二聚化、核转移和转录活性。ODZ10117对STAT3的抑制作用比已知的STAT3抑制剂如S3I-201、STA-21和nifuroxazide更强。ODZ10117抑制了乳腺癌体内外模型的迁移和侵袭，诱导细胞凋亡，减少肿瘤生长和肺转移，并延长了生存率。总的来说，我们证明了ODZ10117是一种新型的STAT3抑制剂，可能是抗癌药物开发的有前途的药物。

表征谱图